The Safety of Melatonin in Humans

Abstract

Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015;61:77–84.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39.

    Article  PubMed  Google Scholar 

  3. 3.

    Andersen LPH, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014;69:1163–71.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Gitto E, Aversa S, Reiter RJ, Barberi I, Pellegrino S. Update on the use of melatonin in pediatrics. J Pineal Res. 2011;50:21–8.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Hartz I, Handal M, Tverdal A, Skurtveit S. Pediatric off-label use of melatonin—a register linkage study between the norwegian prescription database and patient register. Basic Clin Pharmacol Toxicol. 2015;117:267–73.

    CAS  PubMed  Google Scholar 

  6. 6.

    Andersen LPH, Rosenberg J, Gögenur I III. Perioperative melatonin: not ready for prime time. Br J Anaesth. 2014;112:7–8.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. Anesthesiology. 2010;113:968–76.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Barchas J, DaCosta F, Spector S. Acute pharmacology of melatonin. Nature. 1967;214:919–20.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci. 1999;50:271–9.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Seabra ML, Bignotto M, Pinto LR, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29:193–200.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, le Pelzl H, Gotthardt DN, Cekauskas A, Manikas M, Mikalauskas S, Mikalauskene L, Bruns H, Zorn M, Weigand MA, Büchler MW, Schemmer P. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;50:381–8.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Gitto E, Aversa S, Salpietro CD, Barberi I, Arrigo T, Trimarchi G, Reiter RJ, Pellegrino S. Pain in neonatal intensive care: role of melatonin as an analgesic antioxidant. J Pineal Res. 2012;52:291–5.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, Barberi I. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50:756–60.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, Barberi S, Cordaro S, Barberi I. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001;31:343–9.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, Gitto P, Calabrò MP, Barberi I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol. 2004;21:209–16.

    Article  PubMed  Google Scholar 

  16. 16.

    Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, Gitto P, Calabrò MP, Barberi I. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res. 2005;39:287–93.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004;39:184–9.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, Buonocore G, Cordaro V, Trimarchi G, Barberi I. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res. 2004;36:250–5.

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, Whitton C, Tomlinson H, Bennett S, Jardine J, McCaffrey N, Leyland C, Jakeman C, Miles J. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. 2011;41:175–84.

    Article  PubMed  Google Scholar 

  20. 20.

    Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700–9.

    Article  PubMed  Google Scholar 

  21. 21.

    Jain SV, Horn PS, Simakajornboon N, Beebe DW, Holland K, Byars AW, Glauser TA. Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study. Sleep Med. 2015;16:637–44.

    Article  PubMed  Google Scholar 

  22. 22.

    Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, Montgomery P, Whitehouse WP, Choonara I, Allport T, Edmond A, Appleton R, MENDS Study Group. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ. 2012;345:e6664.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  23. 23.

    Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, Hamilton D, Weiss MD. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57–64.

    CAS  PubMed  Google Scholar 

  24. 24.

    Van Geijlswijk IM, Mol RH, Egberts TCG, Smits MG. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology. 2011;216:111–20.

    PubMed Central  Article  PubMed  Google Scholar 

  25. 25.

    Paul MA, Gray G, Kenny G, Pigeau RA. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003;74:1263–70.

    CAS  PubMed  Google Scholar 

  26. 26.

    Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. J Travel Med. 1998;5:7–13.

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Andersen LP, Werner MU, Rosenkilde MM, Fenger AQ, Petersen MC, Rosenberg J, Gögenur I. Pharmacokinetics of high-dose intravenous melatonin in humans. J Clin Pharmacol. 2015. doi:10.1002/jcph.592 [Epub ahead of print].

  28. 28.

    Nordlund JJ, Lerner AB. The effects of ora melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab. 1977;45:768–74.

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Shaw KM, Stern GM, Sandler M. Melatonin and parkinsonism. Lancet. 1973;1:271.

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014;145:683–95.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    De Matos Cavalcante AG, de Bruin PF, de Bruin VM, Nunes DM, Pereira ED, Cavalcante MM, Andrade GM. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study. J Pineal Res. 2012;53:238–44.

  32. 32.

    Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–61.

  33. 33.

    Acil M, Basgul E, Celiker V, Karagöz AH, Demir B, Aypar U. Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol. 2004;21:553–7.

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Borazan H, Tuncer S, Yalcin N, Erol A, Otelcioglu S. Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial. J Anesth. 2010;24:155–60.

    Article  PubMed  Google Scholar 

  35. 35.

    Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. Br J Anaesth. 1999;82:875–80.

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesth Analg. 2000;91:473–9.

    CAS  PubMed  Google Scholar 

  37. 37.

    Mistraletti G, Umbrello M, Sabbatini G, Miori S, Taverna M, Cerri B, Mantovani ES, Formenti P, Spanu P, D’agostino A, Salini S, Morabito A, Fraschini F, Reiter RJ, Iapichino G. Melatonin reduces the need for sedation in ICU patients. A randomized controlled trial. Minerva Anestesiol. 2015 [Epub ahead of print].

  38. 38.

    Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12:R52.

    PubMed Central  Article  PubMed  Google Scholar 

  39. 39.

    Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E, Esposti R, DeMartini G, Fraschini F, Rezzani R, Reiter RJ, Iapichino G. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48:142–7.

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.

    Article  PubMed  Google Scholar 

  41. 41.

    Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008;248:189–98.

    Article  PubMed  Google Scholar 

  42. 42.

    Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77:295–301.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  43. 43.

    Kehlet H. Postoperative opioid sparing to hasten recovery: what are the issues? Anesthesiology. 2005;102:1083–5.

    Article  PubMed  Google Scholar 

  44. 44.

    Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, Santoro D, Arcoraci V, Perrotta M, Ibanez L, Trifirò G. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015;10:e0122899.

    PubMed Central  Article  PubMed  Google Scholar 

  45. 45.

    Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, Sostres C, García-Rodríguez LA. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(906–12):e2.

    PubMed  Google Scholar 

  46. 46.

    Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–35.

  47. 47.

    Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G, REACH Registry Investigators. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol. 2013;163:266–71.

    Article  PubMed  Google Scholar 

  48. 48.

    Klein M, Gögenur I, Rosenberg J. Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data. BMJ. 2012;345:e6166.

    PubMed Central  Article  PubMed  Google Scholar 

  49. 49.

    Davis GF. Adverse effects of corticosteroids: II. Systemic. Clin Dermatol. 2012;4:161–9.

    Article  Google Scholar 

  50. 50.

    Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  51. 51.

    Reiter RJ. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Front Neuroendocrinol. 1995;16:383–415.

    Article  CAS  PubMed  Google Scholar 

  52. 52.

    Srinivasan V, Spence WD, Pandi-Perumal SR, Zakharia R, Bhatnagar KP, Brzezinski A. Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol. 2009;25:779–85.

    Article  CAS  PubMed  Google Scholar 

  53. 53.

    Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20:293–307.

    Article  CAS  PubMed  Google Scholar 

  54. 54.

    Engler AC, Hadash A, Shehadeh N, Pillar G. Breastfeeding may improve nocturnal sleep and reduce infantile colic: potential role of breast milk melatonin. Eur J Pediatr. 2012;171:729–32.

    Article  Google Scholar 

  55. 55.

    Merchant NM, Azzopardi DV, Hawwa AF, McElnay JC, Middleton B, Arendt J, Arichi T, Gressens P, Edwards AD. Pharmacokinetics of melatonin in preterm infants. Br J Clin Pharmacol. 2013;76:725–33.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  56. 56.

    Reiter RJ, Tamura H, Tan DX, Xu XY. Melatonin and the circadian system: contributions to successful female reproduction. Fertil Steril. 2014;102:321–8.

    Article  CAS  PubMed  Google Scholar 

  57. 57.

    Tamura H, Takasaki A, Miwa I, Taniguchi K, Maekawa R, Asada H, Taketani T, Matsuoka A, Yamagata Y, Shimamura K, Morioka H, Ishikawa H, Reiter RJ, Sugino N. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res. 2008;44:280–7.

    Article  CAS  PubMed  Google Scholar 

  58. 58.

    Fourrier A, Letenneur L, Dartigues JF, Moore N, Bégaud B. Benzodiazepine use in an elderly community-dwelling population Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol. 2001;57:419–25.

    Article  CAS  PubMed  Google Scholar 

  59. 59.

    Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;19(348):g1996.

    Article  Google Scholar 

  60. 60.

    Zhdanova IV, Wurtman RJ, Balcioglu A, Kartashov AI, Lynch HJ. Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J Gerontol A Biol Sci Med Sci. 1998;53:B293–8.

  61. 61.

    Gooneratne NS, Edwards AYZ, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52:437–45.

  62. 62.

    Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharm Ther. 2000;67:1–6.

    Article  Google Scholar 

  63. 63.

    Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYPIA2 activity. Br J Clin Pharmacol. 2003;56:679–82.

    PubMed Central  Article  PubMed  Google Scholar 

  64. 64.

    Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, Laine K. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. J Clin Pharmacol. 2008;48:986–94.

    Article  CAS  PubMed  Google Scholar 

  65. 65.

    Ursing C, von Bahr C, Brismar K, Röjdmark S. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005;61:197–201.

    Article  CAS  PubMed  Google Scholar 

  66. 66.

    Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, Staner L. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23:693–705.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lars Peter Holst Andersen.

Ethics declarations

Funding

No source of funding.

Conflict of interest

LPHA, IG, JR and RJR do not have any conflicts of interest to declare.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Andersen, L.P.H., Gögenur, I., Rosenberg, J. et al. The Safety of Melatonin in Humans. Clin Drug Investig 36, 169–175 (2016). https://doi.org/10.1007/s40261-015-0368-5

Download citation

Keywords

  • Melatonin
  • Simple Reaction Time
  • Melatonin Treatment
  • Exogenous Melatonin
  • Mild Adverse Effect